Clinical Trials on NASH in New Zealand

Total 57 results

Aligos Therapeutics

Active, not recruiting

ALG-055009 in Non-cirrhotic Adults With MASH (HERALD) (HERALD)

Nonalcoholic Steatohepatitis | NASH | MASH | Metabolic Dysfunction-Associated Steatohepatitis

United States
Akero Therapeutics, Inc

Recruiting

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NASH/MASH | NAFLD/MASLD

United States, Canada, Puerto Rico, Australia, India
Corcept Therapeutics

Recruiting

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Nonalcoholic Steatohepatitis (NASH) | Metabolic Dysfunction-associated Steatohepatitis (MASH)

United States, Puerto Rico
Gilead Sciences

Completed

Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function

Nonalcoholic Steatohepatitis (NASH) | Primary Sclerosing Cholangitis (PSC)

United States, New Zealand
Akero Therapeutics, Inc

Recruiting

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NASH With Fibrosis | MASH With Fibrosis

United States, Canada, Puerto Rico, Australia, India, France, Italy, Poland, Spain
Gilead Sciences

Completed

Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Fatty Liver Disease (NAFLD)

United States, New Zealand
Novartis Pharmaceuticals

Terminated

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

Non-alcoholic Steatohepatitis NASH

United Kingdom, United States, Australia, New Zealand, Switzerland, Jordan, Georgia, Puerto Rico
Gilead Sciences

Completed

Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

Canada, United States, Hong Kong, United Kingdom, Switzerland, New Zealand
89bio, Inc.

Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

United States
Institute of Liver and Biliary Sciences, India

Withdrawn

Fecal Microbiota Therapy Versus Standard Therapy in Decompensated NASH Related Cirrhosis: A Randomized Controlled Trial.

NASH Related Decompensated Cirrhosis

India
Enyo Pharma

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients

Healthy | NASH - Nonalcoholic Steatohepatitis

Australia
Icahn School of Medicine at Mount Sinai
National Institutes of Health (NIH)

Completed

The Liver in the World Trade Center Health Program General Responder Cohort and Controls

NASH - Nonalcoholic Steatohepatitis | Steatosis of Liver

United States
Hepanova Inc.

Unknown

A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Subjects

Non-Alcoholic Steatohepatitis (NASH)

United States
Blade Therapeutics

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects

NASH - Nonalcoholic Steatohepatitis | Chronic Liver Disease

Australia
Perspectum

Recruiting

Non-Invasive Quantification of Liver Health in NASH (N-QUAN)

NASH - Nonalcoholic Steatohepatitis

United States
Terns, Inc.

Completed

LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

NASH - Nonalcoholic Steatohepatitis

United States
Akero Therapeutics, Inc

Completed

A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

NASH - Nonalcoholic Steatohepatitis

United States, Puerto Rico
Gilead Sciences

Completed

Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis

Nonalcoholic Steatohepatitis (NASH)

United States
Immuron Ltd.

Completed

A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis

Non-alcoholic Steatohepatitis (NASH)

United States, Australia, Israel
Corcept Therapeutics

Terminated

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Hanmi Pharmaceutical Company Limited

Recruiting

Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects

NASH - Nonalcoholic Steatohepatitis

Korea, Republic of, United States
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States, Australia, Puerto Rico
Hepion Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis (ASCEND)

NAFLD | Nonalcoholic Steatohepatitis (NASH) | Fibrosis, Liver

United States, France, Mexico
Poxel SA

Completed

Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)

NASH - Nonalcoholic Steatohepatitis

United States
Viking Therapeutics, Inc.

Active, not recruiting

A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH (VOYAGE)

NASH - Nonalcoholic Steatohepatitis

United States, Belgium, France, Mexico, Puerto Rico
89bio, Inc.
ProSciento, Inc.

Completed

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

NASH

United States, Puerto Rico
Cirius Therapeutics, Inc.
Chiltern International Inc.

Completed

A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH (EMMINENCE)

Non-alcoholic Fatty Liver Disease | NASH - Nonalcoholic Steatohepatitis | Non-alcoholic Steatohepatitis

United States
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH) (FLIGHT-FXR)

Non-alcoholic Steatohepatitis (NASH)

Belgium, Germany, Taiwan, Austria, United States, Spain, Korea, Republic of, Argentina, Australia, Italy, Japan, Singapore, Netherlands, Slovakia, France, Canada, India
Institute of Liver and Biliary Sciences, India

Completed

Effect of Metformin on Disease Progression in Patients With Cryptogenic Cirrhosis (NASH-related Cirrhosis) With Diabetes or Impaired Glucose Tolerance or Insulin Resistance

NASH Related Cirrhosis

India
89bio, Inc.

Active, not recruiting

Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH) (ENLIVEN)

NASH - Nonalcoholic Steatohepatitis

United States, Puerto Rico
Gilead Sciences

Terminated

Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH (NASH)

Liver Fibrosis Due to NASH

United States, Canada, France, Italy, Germany, Puerto Rico, Spain, United Kingdom
Madrigal Pharmaceuticals, Inc.

Recruiting

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

Cirrhosis, Liver | NASH

United States, Puerto Rico
Intercept Pharmaceuticals

Terminated

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

Non Alcoholic Steatohepatitis (NASH)

United States, Finland, France, Spain, United Kingdom, Israel, Austria, Italy, Denmark, Germany, Belgium, Switzerland, Puerto Rico, Poland, Australia, Sweden, Serbia, New Zealand, Canada, Hungary, Portugal
Altimmune, Inc.

Recruiting

Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT Trial) (IMPACT)

Non-Alcoholic Steatohepatitis (NASH)

Australia, United States, Puerto Rico
Boehringer Ingelheim

Completed

A Study to Test Safety and Efficacy of BI456906 in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

Non-alcoholic Steatohepatitis (NASH)

United States, Spain, Korea, Republic of, United Kingdom, Australia, Canada, Singapore, Germany, Italy, Malaysia, China, France, Japan, Taiwan, Netherlands, Austria, Israel, New Zealand, Poland, Hong Kong, Belgium, Czechia, Greece, Hu... and more
Genfit
Premier Research Group plc; Naturalpha

Completed

Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis (NASH)

United States, Belgium, France, Germany, Italy, Netherlands, Romania, Spain, United Kingdom
NGM Biopharmaceuticals, Inc

Completed

Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

NASH - Nonalcoholic Steatohepatitis

United States, Puerto Rico
Madrigal Pharmaceuticals, Inc.

Active, not recruiting

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis (MAESTRO-NASH)

NASH - Nonalcoholic Steatohepatitis

United States, Spain, Australia, United Kingdom, Canada, Israel, Belgium, Italy, France, Puerto Rico, Switzerland, Germany, Austria, Poland, Mexico, Hungary
Genfit

Terminated

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) (RESOLVE-IT)

Nonalcoholic Steatohepatitis (NASH) With Fibrosis

United States, Belgium, Germany, France, Canada, Netherlands, Italy, Switzerland, Finland, Puerto Rico, United Kingdom, Denmark, Spain, Australia, Czechia, Sweden, Romania, Argentina, Portugal, Turkey, Mexico, Colombia, South Africa, ... and more
Inventiva Pharma

Recruiting

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) (NATiV3)

NASH - Nonalcoholic Steatohepatitis

United States, Argentina, Australia, Austria, Belgium, France, Germany, Israel, Portugal, Spain, United Kingdom, Canada, Italy, China, Brazil, Netherlands, Hungary, Bulgaria, Chile, Czechia, Mexico, Poland, Puerto Rico, South Africa, Uk...
Icahn School of Medicine at Mount Sinai

Recruiting

Effect of Music Therapy on Infants With Neonatal Abstinence Syndrome

NAS

United States
Gilead Sciences

Terminated

Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Liver Fibrosis Due to NASH

United States, Spain, France, Canada, Germany, Italy, Puerto Rico, United Kingdom, Belgium
Gilead Sciences

Completed

Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3

Non-Alcoholic Steatohepatitis (NASH)

United States, Canada
Novartis Pharmaceuticals

Terminated

Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis. (ELIVATE)

Non Alcoholic Steatohepatitis (NASH)

United States, South Africa, Spain, Germany, Italy, Taiwan, Canada, Korea, Republic of, Singapore, Bulgaria, Estonia, Mexico, Japan, Denmark, United Kingdom, Colombia, Brazil, Belgium, Russian Federation, Puerto Rico, Chile, Argen... and more
Axcella Health, Inc

Recruiting

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

Non Alcoholic Steatohepatitis (NASH)

United States, Canada, United Kingdom, Australia, France, Poland, Puerto Rico
Bristol-Myers Squibb

Terminated

Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States, Germany, Taiwan, United Kingdom, Spain, Argentina, Brazil, France, Israel, Italy, Japan, Korea, Republic of, Belgium, Canada, Puerto Rico, Switzerland
AstraZeneca

Recruiting

A Trial to Learn How Safe AZD9550 is in People With Type 2 Diabetes Who Are Overweight or Obese (CONTEMPO)

Non-alcoholic Steatohepatitis (NASH)

Austria, Germany, Japan, Sweden
Novartis Pharmaceuticals
Allergan

Completed

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis (TANDEM)

Non-alcoholic Steatohepatitis (NASH)

United States, Belgium, Spain, Canada, Argentina, Israel, Germany, France, Italy, Turkey, Singapore, Russian Federation, United Kingdom, Czechia, Egypt, India, Latvia
Trustees of Dartmouth College
Patient-Centered Outcomes Research Institute

Completed

MOms in REcovery (MORE) Study: Defining Optimal Care (MORE)

Opioid-Related Disorders | Substance Use Disorders | NAS

United States
State University of New York at Buffalo

Recruiting

Blood Collection Biorepository for Liver Disease Research

Fibrosis | Hepatitis B | Hepatitis C | Fatty Liver | Cirrhosis | Bariatric Surgery Candidate | Obesity, Childhood | Non-Alcoholic Steatohepatitis(NASH)

United States

Clinical Trials on NASH in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations